Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Yoshino · SciRah

Researcher profile · Semantic Scholar

T. Yoshino

Share profile

T. Yoshino — researcher profile on SciRah

h-index: 77
Works: 945
Citations: 37K

Most-cited papers

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D. Kotani, E. Oki, Yoshiaki Nakamura, H. Yukami +18 more
2023Nature Medicine496 citations Open access
Semantic Scholar
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
A. Dasari, S. Lonardi, R. García-Carbonero, E. Élez +33 more
2023The Lancet271 citations Open access
Semantic Scholar
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
J. Watanabe, K. Muro, K. Shitara, K. Yamazaki +24 more
2023Journal of the American Medical Association (JAMA)256 citations Open access
Semantic Scholar
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
Y. Kubota, A. Kawazoe, S. Mishima, Y. Nakamura +8 more
2023ESMO Open167 citations Open access
Semantic Scholar
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
T. Yoshino, M. Di Bartolomeo, K. Raghav, T. Masuishi +16 more
2023Nature Communications155 citations Open access
Semantic Scholar
Therapeutic landscape and future direction of metastatic colorectal cancer
H. Bando, A. Ohtsu, T. Yoshino
2023Nature reviews: Gastroenterology & hepatology141 citations
Semantic Scholar
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.
D. Le, L. Diaz, Tae Won Kim, E. Van Cutsem +16 more
2023European Journal of Cancer90 citations
Semantic Scholar
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
T. Yoshino, A. Cervantes, H. Bando, E. Martinelli +29 more
2023ESMO Open85 citations Open access
Semantic Scholar
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer
E. Van Cutsem, J. Taieb, R. Yaeger, T. Yoshino +15 more
2023Journal of Clinical Oncology75 citations Open access
Semantic Scholar
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
Thierry Andre, E. Élez, E. Van Cutsem, Lars Henrik Jensen +16 more
2024Journal of Clinical Oncology55 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
K. Raghav, S. Siena, A. Takashima, T. Kato +16 more
2023Journal of Clinical Oncology55 citations Open access
Semantic Scholar
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
J. Strickler, T. Yoshino, K. Stevinson, C. Eichinger +3 more
2023The Oncologist42 citations Open access
Semantic Scholar
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
K. Umemoto, Y. Sunakawa, M. Ueno, M. Furukawa +22 more
2023British Journal of Cancer29 citations Open access
Semantic Scholar
Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN
S. Mishima, Yoshiaki Nakamura, H. Tukachinsky, H. Taniguchi +19 more
2023The journal of liquid biopsy26 citations Open access
Semantic Scholar
LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
A. Kawazoe, R. Xu, M. Passhak, H. Teng +16 more
2023Annals of Oncology22 citations Open access
Semantic Scholar
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
T. Bekaii-Saab, E. Van Cutsem, J. Tabernero, S. Siena +10 more
2023Journal of Clinical Oncology17 citations
Semantic Scholar
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
K. Sunami, Yoichi Naito, Y. Saigusa, T. Amano +31 more
2023JAMA Oncology16 citations Open access
Semantic Scholar
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
H. Taniguchi, M. Yagisawa, T. Satoh, S. Kadowaki +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
S. Kopetz, T. Yoshino, T. W. Kim, H. Wasan +10 more
2023Journal of Clinical Oncology14 citations
Semantic Scholar
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
Y. Kuboki, T. Terazawa, T. Masuishi, Masato Nakamura +20 more
2023British Journal of Cancer14 citations Open access
Semantic Scholar
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
R. Cohen, M. Raeisi, Q. Shi, B. Chibaudel +16 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
S. Kopetz, T. Yoshino, T. W. Kim, R. Yaeger +15 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
T. Yoshino, J. Taieb, Y. Kuboki, P. Pfeiffer +2 more
2023Therapeutic Advances in Medical Oncology12 citations Open access
Semantic Scholar
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
A. Sobrero, A. Dasari, S. Lonardi, R. García-Carbonero +16 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program
Yoshiaki Nakamura, Riu Yamashita, W. Okamoto, Y. Komatsu +32 more
2023JCO Precision Oncology11 citations Open access
Semantic Scholar
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)
K. Ando, Yoshiaki Nakamura, H. Kitao, M. Shimokawa +24 more
2023British Journal of Cancer11 citations Open access
Semantic Scholar
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab
S. Fukuoka, Y. Koga, M. Yamauchi, S. Koganemaru +12 more
2023Scientific Reports10 citations Open access
Semantic Scholar
A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative
T. Yoshino, Q. Shi, Toshihiro Misumi, H. Bando +4 more
2023Nature Medicine10 citations
Semantic Scholar
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
C. Bokemeyer, F. Ciardiello, O. Dubreuil, J. Guigay +8 more
2023Future Oncology9 citations Open access
Semantic Scholar
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy
Yuji Aoki, Yoshiaki Nakamura, T. Denda, T. Ohta +25 more
2023JCO Precision Oncology9 citations Open access
Semantic Scholar
Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission.
R. Casolino, A. Johns, Mélanie Courtot, R. Lawlor +14 more
2023The Lancet Oncology9 citations Open access
Semantic Scholar
Survival outcomes following salvage abdominoperineal resection for recurrent and persistent anal squamous cell carcinoma.
D. Kitaguchi, Y. Tsukada, M. Ito, S. Horasawa +5 more
2023European Journal of Surgical Oncology9 citations
Semantic Scholar
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
G. Randon, Yoshiaki Nakamura, R. Yaeger, S. Lonardi +18 more
2023Clinical Cancer Research9 citations Open access
Semantic Scholar
Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability–high (MSI-H) locally advanced rectal cancer (LARC).
Y. Tsukada, H. Bando, K. Inamori, M. Wakabayashi +15 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-
Y. Naito, S. Mishima, K. Akagi, N. Hayashi +28 more
2023International Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial.
A. Ohba, C. Morizane, Y. Kawamoto, Y. Komatsu +16 more
2023Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy
N. Aibe, H. Ogino, M. Wakatsuki, K. Fujikawa +22 more
2023Journal of Radiation Research8 citations Open access
Semantic Scholar
Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience
A. Ohtsu, K. Goto, T. Yoshino
2023Proceedings of the Japan Academy. Series B, Physical and biological sciences8 citations Open access
Semantic Scholar
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.
E. Oki, D. Kotani, Yoshiaki Nakamura, S. Mishima +16 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
Shin Kobayashi, H. Bando, A. Taketomi, T. Takamoto +14 more
2023BMC Cancer6 citations Open access
Semantic Scholar
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
S. Mishima, Y. Naito, K. Akagi, N. Hayashi +28 more
2023International Journal of Clinical Oncology6 citations Open access
Semantic Scholar
SO-29 Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
J. Tabernero, E. Van Cutsem, T. Yoshino, R. Yaeger +7 more
2023Annals of Oncology6 citations Open access
Semantic Scholar
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
F. Ou, Daniel H. Ahn, J. Dixon, A. Grothey +27 more
2023Cancers5 citations Open access
Semantic Scholar
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition
S. Mishima, Y. Naito, K. Akagi, N. Hayashi +28 more
2023International Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.
A. Cercek, J. Bachet, J. Capdevila, N. Starling +8 more
2023Journal of Clinical Oncology5 citations Open access
Semantic Scholar
P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer
Y. Takahashi, T. Kato, H. Bando, Y. Tsukada +16 more
2023Annals of Oncology5 citations Open access
Semantic Scholar
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer
Y. Sunakawa, Y. Kuboki, J. Watanabe, T. Terazawa +20 more
2024Targeted oncology4 citations Open access
Semantic Scholar
Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study
S. Yuki, K. Yamazaki, Y. Sunakawa, H. Taniguchi +17 more
2023Cancer Medicine4 citations Open access
Semantic Scholar
Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.
M. Mulcahy, H. Nimeiri, O. Rahma, Jonathan Wills +10 more
2023Journal of Clinical Oncology4 citations
Semantic Scholar
Multiomic analysis for minimal residual disease detection: Addressing challenges in stage II-III colon cancer from COSMOS-CRC-01.
Yoshiaki Nakamura, Y. Tsukada, N. Matsuhashi, T. Murano +16 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Bando×14
Invite
H. Bando — researcher profile on SciRah
E. Oki×13
Invite
E. Oki — researcher profile on SciRah
Yoshiaki Nakamura×13
Invite
Yoshiaki Nakamura — researcher profile on SciRah
T. Kato×12
Invite
T. Kato — researcher profile on SciRah

×10

Invite

H. Taniguchi — researcher profile on SciRah

E. Van Cutsem×10

Invite

E. Van Cutsem — researcher profile on SciRah

Invite

E. Élez — researcher profile on SciRah

Invite

S. Mishima — researcher profile on SciRah

Invite

Y. Sunakawa — researcher profile on SciRah

Invite

K. Yamazaki — researcher profile on SciRah

J. Tabernero×7

Invite

J. Tabernero — researcher profile on SciRah

Invite

Y. Komatsu — researcher profile on SciRah